| Full text | |
| Author(s): |
Acar, Vitoria
[1]
;
Couto Fernandez, Fabio Leite
[2]
;
Buscariolo, Fabio Fabian
[1]
;
Novais, Adriana Alonso
[3]
;
Matheus Pereira, Roseli Aparecida
[4]
;
Pires de Campos Zuccari, Debora Aparecida
[5]
Total Authors: 6
|
| Affiliation: | [1] Sao Jose do Rio Preto Med Sch FAMERP, Sao Jose Do Rio Preto, SP - Brazil
[2] Sao Jose do Rio Preto Med Sch FAMERP, Dept Clin Med, Sao Jose Do Rio Preto, SP - Brazil
[3] Sao Jose do Rio Preto Med Sch FAMERP, Canc Mol Res Lab, Sao Jose Do Rio Preto, SP - Brazil
[4] Sao Jose do Rio Preto Med Sch FAMERP, Dept Nursing, Sao Jose Do Rio Preto, SP - Brazil
[5] Sao Jose do Rio Preto Med Sch FAMERP, Dept Mol Biol, Sao Jose Do Rio Preto, SP - Brazil
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | CLINICAL MEDICINE & RESEARCH; v. 19, n. 4, p. 183-191, DEC 1 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Prostate cancer is the second most common neoplasm among men, with a high mortality rate in advanced stages. Poly (ADP-ribose) polymerase (PARP) plays an important role in repair to DNA damage, being associated with resistance to tumor cell death. Conversely, Caspase-3 is a crucial mediator of programmed cell death, being highly expressed in apoptotic cells.The aim of the present study was to characterize the expression of PARP and Caspase-3 by immunohistochemistry in patients with advanced prostate cancer. PARP and Caspase-3 were independently correlated to patients' evolution, in accordance with the classification of prognostic groups.The increase in PARP expression was positively correlated with tumor patients with poor prognosis (P < 0.0001). In contrast, a decrease in Caspase-3 expression was identified in patients with poor prognosis, when compared with prostate cancer patients with good prognosis (P = 0.0007). Numerically, 92.3% of patients previously classified with poor prognosis showed higher PARP expression, while 93.75% of patients previously classified with good prognosis showed higher levels of Caspase-3.We conclude that PARP and Caspase-3 are potential prognostic markers for prostate cancer patients with different prognosis. (AU) | |
| FAPESP's process: | 19/11381-1 - Immunohistochemistry evaluation of PARP and caspase-3 as prognostic markers in prostate cancer |
| Grantee: | Vitoria Acar |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |